Litcius/Paper detail

Advances in immunotherapy for MMR proficient colorectal cancer

Hazel Lote, Naureen Starling, Rille Pihlak, Marco Gerlinger

2022Cancer Treatment Reviews31 citationsDOIOpen Access PDF

Abstract

Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types and multiple clinical trials have been conducted in MMRp mCRC. In this review we summarise emerging trial data which demonstrate promising immunotherapy combinations in MMRp mCRC. We outline barriers to success, evaluate emerging biomarkers and discuss potential strategies to increase the effectiveness of immunotherapy in MMRp mCRC.

Topics & Concepts

MedicineImmunotherapyColorectal cancerOncologyCancerCancer immunotherapyInternal medicineCancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasImmunotherapy and Immune Responses
Advances in immunotherapy for MMR proficient colorectal cancer | Litcius